Atea Pharmaceuticals, Inc.

NASDAQ:AVIR

Biotechnology

Healthcare
$3.99 -0.81%

-$0.04 today

Market cap
$320.41M
Beta
0.32
P/E (TTM)
-2.0
EPS (TTM)
-$2.14
52W Low $2.78High $6.45

Volume 0.34M

Average 0.34M

AVIR Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

Atea Pharmaceuticals, Inc.NASDAQ: AVIR

Research & Development · Q1 FY2026 · quarter ended Mar 2026

Research & development grows in line with its trailing trend

Q1 FY2026 research & development of $41.13M rose 39.0% year over year, ahead of the +37.4% change in trailing-twelve-month research & development. Sequentially, it fell 14.0% from the prior quarter. Over 3 fiscal years it compounded at +18.6% a year.

Context

  • Research & development increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +39.0% holds above the trailing-twelve-month pace of +37.4%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$41.13M-14.0% QoQ
Last fiscal yearDec 2025
$148.02M+1.8% YoY
LTMMar 2026
$159.57M+37.4% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+39.0%——
1 year+1.8%——
3-year CAGR+18.6%——
5-year CAGR——
10-year CAGR——

Research & Development history

USD · from the income statement

Latest · FY2025
148.02M USD
Year-over-year change
+1.8%
4-year CAGR
-3.0%

Research & Development vs competitors

How AVIR compares with its peers on the latest reported figures

  • AVIR's LTM Mar 2026 research & development of $159.57M is the 2nd highest of the 5 companies compared; the peer median is $78.09M.
  • Its year-over-year change of +37.4% is the highest of 5, against a peer median of -17.9%.
  • Over three fiscal years its annual growth of +18.6% compares with a peer median of -8.2%.
AVIR Competitors Peer median
Research & Development for AVIR and competitors
Company Period LTM YoY 3-year CAGR% of revenue
VIRVir Biotechnology, Inc.LTM Mar 2026$446.24M -15.0%-3.0%681.3%
AVIRAtea Pharmaceuticals, Inc.LTM Mar 2026$159.57M +37.4%+18.6%—
ENTAEnanta Pharmaceuticals, Inc.LTM Mar 2026$91.32M -20.8%-13.4%131.9%
ASMBAssembly Biosciences, Inc.LTM Mar 2026$64.86M +10.1%-2.5%91.2%
ABUSArbutus Biopharma CorporationLTM Mar 2026$20.4M -57.1%-33.1%10.7%
Peer median (excluding AVIR) $78.09M-17.9%-8.2%111.6%

Competitors are the stored peer set for AVIR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue351.37M0000
Cost of Revenue167.21M62.39M70.09M83.37M0
Gross Profit184.16M(62.39M)(70.09M)(83.37M)0
Gross Margin52.4%————
Research & Development167.21M88.84M132.84M145.4M148.02M
Selling, General & Admin45.79M48.71M49.92M48.85M32.86M
Operating Expenses45.79M68.26M94.07M109.58M180.89M
Depreciation & Amortization29K260K416K416K416K
EBITDA138.62M(110.84M)(119.59M)(131.8M)(164.1M)
EBITDA Margin39.5%————
Operating Income138.38M(130.65M)(164.16M)(192.95M)(180.89M)
Operating Margin39.4%————
Interest Income213K11.15M29.22M25.49M16.38M
Interest Expense011.15M000
Other Income / Expenses213K11.15M29.22M25.49M16.38M
Income Before Tax138.59M(119.5M)(134.94M)(167.46M)(164.51M)
Pre-Tax Margin39.4%————
Income Tax Expense17.4M(3.59M)1.02M925K(6.16M)
Net Income121.19M(115.91M)(135.96M)(168.39M)(158.35M)
Net Margin34.5%————
EPS (Basic)1.46(1.39)(1.63)(2.00)(1.94)
EPS (Diluted)1.37(1.39)(1.63)(2.00)(1.94)
Weighted Avg Shares82.82M83.25M83.39M84.26M81.5M
Weighted Avg Shares (Diluted)88.25M83.25M83.39M84.26M81.5M

Atea Pharmaceuticals, Inc.

NASDAQ:AVIR

Intrinsic Alpha fair value

Locked

Current Price

$3.99

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.